Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr113.60 SEK
Change Today -1.00 / -0.87%
Volume 574.4K
As of 11:30 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/11/15 - kr145.90
52 Week Low
10/16/14 - kr65.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; Xiapex for the treatment of Peyronie’s disease; and Yondelis for the treatment of a type of cancer. The company also offers Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. In addition, it provides Aloxi, Betapred, ChondroCelect, Collatamp, Cometriq, Defibrotide, Erwinase, Ferriprox, Fosinopril, Kepivance, Megestrol, Ruconest, and Willfact for the treatment of rare diseases. Further, the company’s rFVIIIFc and rFIXFc are development projects in pipeline for the treatment of hemophilia; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002 is in Phase I clinical trials. It also manufactures drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A. The company has an agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

648 Employees
Last Reported Date: 07/16/15

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.4M
Compensation as of Fiscal Year 2014.

swedish orphan biovitrum ab (SOBI) Key Developments

Swedish Orphan Biovitrum AB (Publ) Announces Earnings Results for the Second Quarter and Six Months of 2015; Revises Earnings Guidance for the Full Year of 2015

Swedish Orphan Biovitrum AB (publ) announced earnings results for the second quarter and six months of 2015. For the quarter, revenues for the quarter totaled SEK 764 million compared to SEK 663 million, an increase of 15% year-on year. EBITA was SEK 74 million compared to SEK 86 million a year ago. EBIT was SEK 3 million compared to SEK 16 million a year ago. Profit for the period was SEK 9 million compared to SEK 26 million a year ago. For the six months, revenues for the quarter totaled SEK 1,629 million compared to SEK 1,236 million, an increase of 32% year-on year. EBITA was SEK 247 million compared to SEK 123 million a year ago. EBIT was SEK 105 million compared to LBIT of SEK 342 million a year ago. Profit for the period was SEK 115 million compared to loss for the period of SEK 303 million a year ago. The company now expects total revenues for the full year to be in the range of SEK 3,000 million to 3,200 million, compared to previously SEK 2,800 million to 3,000 million and gross margin to be in the range of 59% to 61% compared to previously 58% to 60%. The company expects EBITA to be in the range of SEK 325 million SEK 400 million.

Swedish Orphan Biovitrum AB, Q2 2015 Earnings Call, Jul 16, 2015

Swedish Orphan Biovitrum AB, Q2 2015 Earnings Call, Jul 16, 2015

Biogen and Swedish Orphan Biovitrum AB (publ) Announce European Medicines Agency Validates Alprolix Marketing Authorization Application

Biogen and Swedish Orphan Biovitrum AB (publ) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of ALPROLIX (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process. The MAA includes results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics (a measure of the presence of the therapy in a person’s body over time) of ALPROLIX for hemophilia B: the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12. ALPROLIX is a recombinant, clotting factor IX therapy and is currently approved for the treatment of hemophilia B in the U.S., Canada, Japan and Australia. It is the only approved hemophilia B therapy to demonstrate prolonged clotting factor circulation in the body. Biogen and Sobi are collaborators in the development and commercialization of ALPROLIX for hemophilia B. Sobi has an opt-in right to assume final development and commercialization of ALPROLIX for the Sobi territories (essentially, Europe, North Africa, Russia and certain Middle Eastern markets). Biogen leads development for ALPROLIX, has manufacturing rights, and has commercialization rights in North America and all other regions in the world excluding the Sobi territories.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr113.60 SEK -1.00

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €13.32 EUR +0.085
Oxford Biomedica PLC 9.24 GBp +0.24
Veloxis Pharmaceuticals A/S kr1.06 DKK 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SOBI Industry Range
Price/Earnings 100.0x
Price/Sales 9.7x
Price/Book 6.2x
Price/Cash Flow 196.4x
TEV/Sales 9.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at